TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V330
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection
Study: NCT05727813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: cryoablation of breast cancer smaller than 2 cm
Study: NCT05234957

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lateral Rectus Recession
Description: Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Lateral Rectus Recession
Description: Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
Study: NCT04764513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded γδ T cell infusion
Description: Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10\^6、 1×10\^7 and 5×10\^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1.
Study: NCT05336903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP-led model of care for chronic pain management
Description: The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options.
Study: NCT05826067

Intervention type: OTHER
Intervention: collection of bacterial strains
Description: Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
Study: NCT04917965

Intervention type: OTHER
Intervention: Laboratory clotting studies
Description: Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s

Intervention type: OTHER
Intervention: Laboratory clotting studies
Description: Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
Study: NCT06161129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenses
Description: The filter lenses will be worn by participants for one month all day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenses
Description: The filter lenses will be worn by participants for one month all day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenses
Description: The filter lenses will be worn by participants for one month all day.
Study: NCT05663333

Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of temporal artery biopsy
Description: Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
Study: NCT05344391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR cycling
Description: Cycling with BFR followed by shoulder exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling without BFR
Description: Cycling without BFR followed by shoulder exercises
Study: NCT05245461

Intervention type: OTHER
Intervention: Assessments
Description: Muscle Strength, Proprioception, Kinesiophobia
Study: NCT05028374

Intervention type: DRUG
Group type: OTHER
Intervention: A single booster dose of the Moderna mRNA COVID-19 vaccine
Description: All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
Study: NCT05127109

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutrition Ecosystem pathway
Description: 1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: retrospective cohort of 300 historical matched control subjects
Study: NCT06193642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
Study: NCT05423314

Intervention type: PROCEDURE
Intervention: knee brace cold therapy
Description: receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase.
Study: NCT05309902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablet.
Study: NCT05437731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coated titanium mesh
Description: patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated titanium mesh
Description: patients will undergo reconstruction using the conventional uncoated titanium mesh.
Study: NCT06364007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+STRIDE+Len
Description: patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
Study: NCT05448469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plane block
Description: patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided paravertebral block
Description: patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional analgesia
Description: patients will receive combined general anesthesia and conventional analgesia
Study: NCT00246675

Intervention type: DRUG
Group type: OTHER
Intervention: Frusemide

Intervention type: DRUG
Group type: OTHER
Intervention: Frusemide
Study: NCT05309902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soticlestat placebo-matching tablet.
Study: NCT06046404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed reduction
Description: the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no closed reduction
Description: no reduction will be performed
Study: NCT05679193

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily
Study: NCT05959824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OR-AT0222
Description: Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
Study: NCT04666935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program
Description: Sport Injury Prevention Program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm up
Description: Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
Study: NCT05309902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soticlestat placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soticlestat placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soticlestat placebo-matching tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.
Study: NCT06361368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS150
Description: Participants took one capsule with PS150 after dinner for 30 days.
Study: NCT05309902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Moxifloxacin placebo-matching capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Moxifloxacin placebo-matching capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Moxifloxacin placebo-matching capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Moxifloxacin placebo-matching capsule.
Study: NCT06361368

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants took one capsule with placebo after dinner for 30 days.
Study: NCT05316376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
Study: NCT05785182

Intervention type: PROCEDURE
Intervention: Open Fracture
Description: Patients 18 years of age or older with open fracture. Provision of informed consent.

Intervention type: PROCEDURE
Intervention: Infected Fracture
Description: Patients 18 years of age or older with infected fracture. Provision of informed consent.
Study: NCT05324384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Use of different doses of the same drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study: NCT05567302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
Study: NCT05952102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil capsule
Description: Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Study: NCT05659199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave
Description: Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave
Description: Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
Study: NCT05577559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intermediate cervical plexus block
Description: patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Erector spinae block
Description: patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
Study: NCT04150419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Attentional training to avoid threatening, negative or pain-related information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Attention training for vigilance for positive emotional information.
Study: NCT05761314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular characterization of solid tumor in RASopathies
Description: NGS analysis on tumor sample
Study: NCT06578390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneal device
Description: Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
Study: NCT04586673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1 (C1)
Description: ChAdOx1.tHIVconsv1 5 x 10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1 (C1)
Description: ChAdOx1.tHIVconsv1 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3 (M3)
Description: MVA.tHIVconsv3 1 x 10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4 (M4)
Description: MVA.tHIVconsv4 09. x 10\^8 pfu
Study: NCT04939298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
Study: NCT05056116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Toripalimab
Description: Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
Study: NCT06584240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: Single treatment, intramuscularly injected. The total injection 100-150U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: Single treatment, intramuscularly injected. The total injection 200-250U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3
Description: Single treatment, intramuscularly injected. The total injection 350-400U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: Single treatment, intramuscularly injected. The total injection ≤400U.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sequence 5
Description: Single treatment, intramuscularly injected.
Study: NCT05751369

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education plus Support
Description: Brief behavioral support for using TECW Tracker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education plus Support
Description: Brief behavioral support for using TECW Tracker
Study: NCT05866614

Intervention type: DRUG
Intervention: Remsima IV
Description: Patient will be treated with Remsima IV as per the SmPC or

Intervention type: DRUG
Intervention: Remsima SC
Description: Patient will be treated with Remsima SC as per the SmPC

Intervention type: DRUG
Intervention: Remsima SC
Description: Patient will be treated with Remsima SC as per the SmPC
Study: NCT05975762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical rib fixation
Description: open reduction and internal rib fixation
Study: NCT05287581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVES
Description: The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.